Saccharomyces Boulardii
Natural health product licensed in Canada
- Other names
- Lalflor
- Licence holder
- Lallemand Health Solutions (Institut Rosell)
- NPN or DIN-HM
- 80021796
- Status
- Active licence
- Licence date
- 19 October 2010
- Revision date
- 12 October 2022
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Fécule de pomme de terre, Stéarate de magnésium, Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Nourrissons | maximum: 1 year | 1 Capsule | minimum: 1 Tous les jours ; maximum: 2 Tous les jours |
| Adultes | minimum: 18 years | 1 Capsule | 1 Tous les jours |
| Adultes, adolescents et enfants | minimum: 1 year | 2 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
1 capsule per day: Probiotic to confer a health benefit. Per day provide live microorganisms to confer a health benefit. Provides intestinal comfort for travellers. Helps to reduce the risk of traveller's diarrhea. Source of probiotics. Could promote a favorable gut flora. Helps support gastrointestinal health. Helps support a healthy microbiome. 2 capsule per day: Helps reduce the risk of antibiotic associated diarrhea. Helps to prevent antibiotic associated diarrhea in adults. Helps to prevent antibiotic-associated diarrhea in children. Helps prevent antibiotic associated diarrhea. Helps to treat acute infectious diarrhea in children. Helps reduce the symptoms related to acute infectious diarrhea. An adjunct to physician-supervised antibiotic therapy in patients with Helicobacter pylori infections. An adjunct to physician-supervised antibiotic therapy in hospitalized patients with C. difficile infections/ Clostridium difficile Associated Diarrhea (CDAD) Help reduce the risk of AAD in hospitalized patients at risk of Clostridium difficile Associated Diarrhea (CDAD) Reduces the risk of recurrent C. difficile infection in conjunction with a physician supervised antibiotic therapy Help to reduce the risk of Clostridium difficile. Associated Diarrhea (CDAD) when used as an adjunct to antibiotics (in hospitalized patients).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Source
Official Health Canada record, licence 80021796
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2022. Photograph the packaging to check whether it has changed. Photograph the packaging